Abemaciclib With Letrozole in Recurrent or Persistent Endometrial Cancer

Study Overview

This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer.

The drugs involved in this study are:

  • Abemaciclib (also known as Verzenio(TM))
  • Letrozole (also known as Femara(R))

Study Description

A Phase 2 Study of Abemaciclib with Letrozole in Recurrent or Persistent Endometrial Cancer

  • ClinicalTrials.gov Identifier: NCT03675893
  • Protocol Number: 18-301
  • Principal Investigator: Meghan Shea

Recruitment Status


Contact the research team to learn more about this study.

Fields marked with asterisk (*) are required

Please verify that you are not a bot.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

If you need assistance finding a study or if you have any questions, call us at 617-667-7000